High dose group

DRUG5 trials

Sponsors

Ahon Pharmaceutical Co., Ltd., José Antonio Hurtado Suazo, Beijing Tiantan Hospital, Hangzhou Sumgen Biotech Co., Ltd., Kyambadde Ronald

Conditions

Advanced Breast CancerIntraventricular HemorrhageNecrotizing EnterocolitisPaediatricsPremature InfantsPrimary Immune Thrombocytopenia

Phase 1

Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects

CompletedNCT06290466

Ahon Pharmaceutical Co., Ltd.Advanced Breast Cancer

Start: 2022-11-11End: 2023-02-08Updated: 2024-03-04

rhTNK-tPA Thrombolytic Removal of Intraventricular Hemorrhage

RecruitingNCT06814964

Beijing Tiantan HospitalIntraventricular Hemorrhage

Start: 2025-03-01End: 2025-06-01Target: 18Updated: 2025-02-27

Phase 2

SG301-SC Injection Safety Study in Subjects With Primary ITP Patients

RecruitingNCT07710248

Hangzhou Sumgen Biotech Co., Ltd.Primary Immune Thrombocytopenia

Start: 2026-06-11End: 2027-05-17Target: 60Updated: 2026-09-09

Unknown Phase

PREMAPROB. Probiotics to Prevent Necrotizing Enterocolitis

CompletedNCT06501404

José Antonio Hurtado SuazoPremature Infants, Necrotizing Enterocolitis

Start: 2015-01-10End: 2020-03-20Updated: 2024-07-15

High-dose vs. standard-dose caffeine therapy for apnea of prematurity.

Active, not recruitingPACTR202604505368563

Kyambadde RonaldPaediatrics

Start: 2025-10-21Target: 122Updated: 2026-08-03

Related Papers

No QTc prolongation with CDK 4/6 inhibitor FCN-437c: results of a concentration-QTc analysis from a dedicated study in adult healthy subjects

Frontiers in Pharmacology2024-08-121 citations